Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinato, David J., Mauri, Francesco A., Spina, Paolo, Cain, Owen, Siddique, Abdul, Goldin, Robert, Victor, Stephane, Pizio, Corinna, Akarca, Ayse U., Boldorini, Renzo L., Mazzucchelli, Luca, Black, James R. M., Shetty, Shishir, Marafioti, Teresa, Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738063/
https://www.ncbi.nlm.nih.gov/pubmed/31061454
http://dx.doi.org/10.1038/s41416-019-0466-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738063/
https://www.ncbi.nlm.nih.gov/pubmed/31061454
http://dx.doi.org/10.1038/s41416-019-0466-x

Ejemplares similares